ABSTRACT
We report on a Pashtun family affected by haemoglobin D-Punjab/β+-thalassemia to increase the awareness of the increasing prevalence of haemoglobinopathies among primary care physicians. We highlight the diagnostic approach of these conditions and the benefits of genetic counselling.

INTRODUCTION
Inherited disorders of haemoglobin (Hb) affect approximately 7% of the global population and represent a major health problem.1 The incidence of haemoglobinopathies in previously non-endemic countries in Europe has been increasing steadily as a result of multi-ethnic immigration.2 3 Structural variants are caused by point mutations (eg, Hbs S, C, E, D-Punjab, O-Arab) or by unequal crossover events between the δ-globin and β-globin genes (Hb Lepore) that result in Hb molecules of varying stability and oxygen affinity. The thalassemias result from defective synthesis of the α-globin or β-globin chains that make up the tetrameric human Hbs and are encoded on chromosome 16 and on chromosome 11, respectively.4 The α-thalassemias are characterised by a decrease in the amount of alpha chains. This results in an excess of β-globin molecules that precipitate, and subsequently cause increased destruction of erythrocytes.5 The degree of clinically manifest impairment depends on the number of α-globin genes affected. The β-thalassemias are phenotypically diverse, that is, from transfusion-dependent to asymptomatic microcytic hypochromic anaemia, as a result of an imbalance in α-globin and β-globin chain production. Synthesis of β-globin chain can be partially reduced (β+) or completely silenced (β0). Because of the wide geographic distribution of β-globin chain defects that are inherited in homozygous or compound heterozygous combinations, the β-thalassemias constitute the most important global public health problem.6 We report on a Pashtun family affected by Hb D-Punjab/β+-thalassemia, to increase the awareness of the increasing prevalence of haemoglobinopathies as a result of migration in multi-ethnic populations, to highlight the diagnostic approach of these conditions and the benefits of genetic counselling and to characterise the clinical relevance of our findings.

HAEMATOLOGICAL ANALYSIS OF AN AFGHAN FAMILY
A 38-year-old woman presented with severe microcytic, hypochromic anaemia during the second trimester of her eighth pregnancy. We found abnormal haemograms in her family members’ blood samples that were obtained for unrelated conditions. We therefore analysed this non-consanguineous Pashtun family living in Belgium for haemoglobinopathies (table 1). The mother (patient 2) had an anaemia related to iron deficiency, but only minor response to oral iron suppletion treatment. Automated capillary zone electrophoresis (CZE) was performed on the Minicap Flex Piercing CZE system (Sebia; Norcross, Georgia, USA) according to manufacturer’s instructions and showed a variant elution pattern of Hb haemolysates, suggesting heterozygosity for a Hb D-Punjab Hb variant (table 1 and figure 1).

The 9-year-old son (patient 6) had mild anaemia with erythrocytosis (table 1) and a blood smear showing microcytic, hypochromic red blood cells, schistocytes, target cells and spherocytes. The CZE pattern showed Hb A 3.5%, Hb A2 4.7%, Hb F <0.5% and Hb D 91.8% (figure 1B). The high amount of the Hb D variant with a low fraction of Hb A in absence of a history of red blood cell transfusions suggested compound heterozygosity for Hb D/β+-thalassemia.7

The father (patient 1) was not anaemic, but a marked erythrocytosis, microcytosis and hypochromasia with normal serum ferritin levels (82 μg/L), a high amount of Hb A2 4.3% and absence of a Hb variant suggested a β-thalassemia trait (figure 1C). The other members of the family, that is, patients 3, 5, 8, 9 had a haemogram within the reference range and a normal profile at CZE, while patients 4 and 7 had a phenotype compatible with a heterozygosity for Hb D-Punjab and a beta-thalassemia trait, respectively. Patient 6 had a phenotype compatible with a compound heterozygosity for Hb D/β+-thalassemia.

We evaluated the red cell osmotic fragility for the family members of whom fresh EDTA was available (figure 2), using the ‘naked eye single tube red cell osmotic fragility test’ (NESTROFT), a low cost screening test for β-thalassemia trait.8 9 Briefly, this test is based on the reduced osmotic fragility of red cells in β-thalassemia, that results in persistent turbidity 20 min after suspending 20 μL of fresh EDTA blood into a tube containing 4 mL of a 0.36% hypotonic saline solution. The tube is then held against a white paper with a thin black line. If the line is not visible or blurred, the test is considered positive, that is, reduced osmotic fragility.

---

1Department of Clinical Sciences, Institute of Tropical Medicine, Antwerpen, Belgium
2Service de Génétique—Centre de Génétique humaine de l’ULB, Université Libre de Bruxelles, Bruxelles, Belgium
3Department of Clinical Chemistry, Université Libre de Bruxelles, Bruxelles, Belgium

Correspondence to Dr Ralph Huits, Department of Clinical Sciences, Institute of Tropical Medicine, Antwerpen, Belgium; rhuits@itg.be

Received 26 October 2021
Accepted 4 January 2022

© Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.
If the line is clearly visible through the contents of the tubes, the test is negative. Reduced osmotic fragility was detected in patients 1, 6 and 7.

The hemoglobinopathies that affect this family were characterised at a molecular level by massive parallel sequencing of the whole coding sequence of the HBB genes in the parental blood samples. We identified a heterozygous mutation HBB:c.364G>C (p.Glu122Gln), known as Hb D-Punjab in the mother. The father was found to be heterozygous for HBB:c.92+5G>C, a \( \beta^+ \) type mutation known as IVS1-5 (G>C). By extrapolation, we assigned the \( \beta \)-chain genotypes and Hb chain designations to the other members of the family (table 2).

**DISCUSSION**

Hb D-Punjab (also known as Hb D-Los Angeles) was first described in 1951.\(^7\) It is prevalent in Punjab region, North-west India (estimated frequency 2.0%), but it has also been reported in Italy, Belgium, Austria, Turkey, China and Brazil.\(^4\) Hb D is a stable Hb variant, with only mildly reduced oxygen affinity compared with Hb A.\(^9\) In classic electrophoresis of the Hb D is a stable Hb variant, with only mildly reduced oxygen affinity compared with Hb A.\(^9\) In classic electrophoresis of the Hb D/Punjab trait is clinically

**Table 1** Red blood cell analysis and ferritin levels of the family affected with Hb D and \( \beta^+ \)-thalassemia trait

| Patient | Gender | Hb (g/L) | RBC (*10^12/L) | Ht (L/L) | MCH (pg) | MCV (fL) | RDW (%) | Reticulo (%) | PLT (×10^12/L) | Ferritin (µg/L) |
|---------|--------|----------|----------------|---------|----------|---------|---------|-------------|----------------|----------------|
| 1       | M      | 134      | 7.08           | 0.429   | 19       | 60.5    | 13      | 17.32       | 402            | 82             |
| 2       | F      | 77       | 3.97           | 0.249   | 19.4     | 62.8    | 16.4    | 34.76       | 358            | 8              |
| 3       | F      | 130      | 4.57           | 0.383   | 28.3     | 83.8    | 12.4    | 16.22       | 345            | 13             |
| 4       | F      | 139      | 5.31           | 0.406   | 26.2     | 76.5    | 12      | 12.19       | 367            | 8              |
| 5       | M      | 139      | 5.17           | 0.418   | 26.8     | 80.9    | 12.9    | 11.81       | 318            | 32             |
| 6       | M      | 115      | 6.98           | 359     | 16.5     | 51.4    | 12      | 16.65       | 410            | 28             |
| 7       | F      | 112      | 6.6            | 0.369   | 17       | 55.8    | 11.9    | 18.12       | 363            | 27             |
| 8       | M      | 125      | 4.86           | 0.367   | 25.7     | 75.6    | 11.3    | 8.74        | 445            | ND             |
| 9       | F      | 110      | 4.65           | 0.336   | 23.8     | 72.2    | 13.3    | 13.29       | 449            | ND             |

f, female; Hb, haemoglobin; Ht, haematocrit; M, male; MCH, mean corpuscular haemoglobin; MCV, mean corpuscular volume; ND, not done; PLT, platelet count; RBC, red blood cells; RDW, red cell distribution width; reticulo, reticulocytes.

The prevalence of \( \beta \)-thalassemia in Afghanistan is probably high, but reliable epidemiological data are scarce. Based on a \( \beta \)-thalassemia syndrome prevalence of 3.8% among 369 outpatients, one study estimated a number of 1 to 1.5 million \( \beta \)-thalassemia carriers in Afghanistan.\(^1\) The HBB:c.92+5G>C substitution is the most common \( \beta \)-thalassemia mutation in South Asia, with reported allele frequencies of 64.6%, 56.3% and 36.5% in Sri Lanka, India and Pakistan, respectively.\(^12\) An evolutionary explanation for the widespread distribution of the line is clearly visible through the contents of the tubes, the test is negative. Reduced osmotic fragility was detected in patients 1, 6 and 7.

The hemoglobinopathies that affect this family were characterised at a molecular level by massive parallel sequencing of the whole coding sequence of the HBB genes in the parental blood samples. We identified a heterozygous mutation HBB:c.364G>C (p.Glu122Gln), known as Hb D-Punjab in the mother. The father was found to be heterozygous for HBB:c.92+5G>C, a \( \beta^+ \) type mutation known as IVS1-5 (G>C). By extrapolation, we assigned the \( \beta \)-chain genotypes and Hb chain designations to the other members of the family (table 2).

**DISCUSSION**

Hb D-Punjab (also known as Hb D-Los Angeles) was first described in 1951.\(^7\) It is prevalent in Punjab region, North-west India (estimated frequency 2.0%), but it has also been reported in Italy, Belgium, Austria, Turkey, China and Brazil.\(^4\) Hb D is a stable Hb variant, with only mildly reduced oxygen affinity compared with Hb A.\(^9\) In classic electrophoresis of the Hb fractions, Hb D-Punjab migrates with Hb S under alkaline pH, and with Hb A under acid pH.\(^4\) Modern automated high-throughput methods, such as high-performance liquid chromatography and Hb CZE identify clinically relevant Hb variants with approximately 100% sensitivity and specificity greater than 90%.\(^4\) Hb D-Punjab can be inherited in at least four different states: heterozygous, homozygous Hb D disease, or compound heterozygous states like Hb D-thalassemia (Hb D/\( \beta^+ \)) and co-inheritance with other Hb variants. The more severe co-inheritance is the association between Hb D-Punjab and Hb S that leads to similar clinical and haematological manifestations as in sickle cell anaemia. A couple at risk should be referred for counselling. Because Hb D-Punjab trait is clinically silent, we consider the CZE detection of the mother’s Hb D-carrier status an incidental finding. As indicated by the low serum ferritin level, her microcytic anaemia was explained by iron depletion that showed only mild improvement in response to oral iron suppletion treatment during pregnancy.

The remarkably high Hb D fraction (91.8%) in patient 6 could be mistaken for homozygous Hb D disease, a condition that is not associated with haematological or clinical manifestations. A recent study suggested that a Hb D fraction greater than 92% can be used to discriminate homozygotes from Hb D-Punjab/\( \beta \)-thalassemia double heterozygotes.\(^10\) However, the finding of hypocromic, microcytic red cell morphology with erythrocytosis in the presence of Hb A and an elevated Hb A2 fraction alerted us to the possible coinheritance of a \( \beta \)-thalassemia trait in our patient. The presence of a \( \beta^+ \)-thalassemia trait was confirmed by genetic testing of the father.

The prevalence of \( \beta \)-thalassemia in Afghanistan is probably high, but reliable epidemiological data are scarce. Based on a \( \beta \)-thalassemia syndrome prevalence of 3.8% among 369 outpatients, one study estimated a number of 1 to 1.5 million \( \beta \)-thalassemia carriers in Afghanistan.\(^1\) The HBB:c.92+5G>C substitution is the most common \( \beta \)-thalassemia mutation in South Asia, with reported allele frequencies of 64.6%, 56.3% and 36.5% in Sri Lanka, India and Pakistan, respectively.\(^12\) An evolutionary explanation for the widespread distribution of the

**Figure 1** Elution pattern of hemolysates on the Minicap Flex Piercing CZE system (patients 2, 6 and 1). / Hemoglobin electrophoresis patterns of patient 2, patient 6 and patient 1 are shown. Normal values for the Hb-fractions on the Minicap Flex Piercing CZE system (Sebia; Norcross, GA, USA) are Hb A 96.8-97.8%; Hb A2 2.2-3.2%; and Hb F ≤ 0.5%. Patient 2 (A), a Hb D carrier, has a decreased Hb A (60.8%), a normal Hb A2 (2.3%) and an additional Hb D fraction (36.9%). Patient 6 (B), a Hb D/\( \beta^+ \)-thalassemia compound heterozygote, has a greatly decreased Hb A (3.5%), an increased Hb A2 (4.9%) and a greatly increased Hb D fraction (91.8%). Patient 1 (C) has a decreased Hb A (95.1%), an increased Hb A2 (4.3%) and a slightly increased for Hb F fraction (0.6%), a pattern compatible with \( \beta \)-thalassemia trait.
Short report of β-thalassemia in the WHO Eastern Mediterranean Region remains elusive. Although Haldane postulated that heterozygosity for β-thalassemia protects against severe falciparum malaria in 1949, this hypothesis remains to be evaluated in prospective clinical studies.13 14 However, persistence of thalassemia genes in many populations can largely be attributed to consanguinity, a known risk factor for all recessive genetic disorders. The proportion of consanguineous marriages among populations of Afghanistan was found to be as high as 46.2%.15 So, what is the clinical relevance of diagnosing the Hb D-Punjab and β+-thalassemia traits? Hb D in a heterozygous or even in a homozygous state is asymptomatic. Although compound heterozygote Hb D/β-thalassemia cases that needed blood transfusions have been reported, Basmanj et al did not observe profoundly anaemic or transfusion dependent Hb D/β-thalassemia compound heterozygotes after screening more than 8000 β-thalassemia carriers.16 In a recent practice guideline, compound heterozygote Hb D/β-thalassemia was reported as not clinically relevant, and no prenatal diagnosis is warranted.17 As outlined in the introduction, all β-thalassemia traits can be inherited in deleterious homozygous or compound heterozygous combinations. Therefore, premartial or antenatal screening for these haemoglobinopathies is important. In chronic microcytic anaemia, distinguishing β-thalassemia trait from iron deficiency is important to avoid unnecessary and potentially harmful iron treatment. In addition, a study from Sri Lanka found that people with β-thalassemia trait had symptoms suggestive of anaemia, including lethargy, fatigue and dizziness compared with normal subjects, and they visited their physicians more frequently.18 Surprisingly, the latter study also found that patients with β-thalassemia trait experienced significantly more fever episodes that necessitated medical attention than controls.18 In many countries with high carrier rates, nationwide screening programmes for the hemoglobinopathies have been established.19 In 2014, a pan-European expert consensus recommended newborn screening in Europe to target only sickle cell disease, that is, Hb S.19 In previously non-endemic countries with high rates of multi-ethnic immigration antenatal screening programmes may be absent. In these countries, primary care professionals can play an important role in the identification of individuals and families at risk by detailed family medical history taking and by offering screening and genetic counselling. A high index of suspicion is required to differentiate between thalassemias and iron deficiency anaemia (IDA), especially when microcytic anaemia is accompanied by normal iron studies. Many mathematical indices have been used to discriminate thalassemia

![Figure 2](http://jcp.bmj.com/jclinpath/2021-208009 on 17 January 2022. Downloaded from http://jcp.bmj.com)
trait from IDA (eg, Mentzer’s index that suggests mean corpuscular volume/red blood cell <13 for thalassemia and >14 for IDA). A meta-analysis found that although these indices lack diagnostic accuracy to confirm thalassemia, they are valuable for the identification of subjects in whom further diagnostic testing is indicated, especially when combined with other factors, such as age, ethnicity or family history. In resource limited countries with high prevalence of thalassemias, red cell osmotic fragility testing is used for population screening. For the NESTROFT test we used, Singh et al reported 97.7% sensitivity and 83.3% specificity for the detection of β-thalassemia trait. As stated above, modern laboratories use red cell morphology and automated high-throughput methods for the routine diagnosis of hemoglobinopathies.

Molecular diagnosis of hereditary HB disorders is only mandatory for antenatal diagnosis. It can further be performed for confirmation, prognosis or treatment of putative haemoglobinopathies that may harm the patient or his/her offspring, or as was done in this case series, for a phenotype–genotype correlation.

CONCLUSION
We described an immigrant Pashtun family affected by Hb D Punjab/β+-thalassemia. Following migratory flows, this case highlights the variety of haemoglobinopathies that general practitioners in non-endemic countries may encounter. Basic diagnostic tests such as a complete blood count, red cell indices and morphology, complemented by (automated) separation and measurement of Hb fractions assist primary care physicians in identifying common traits. For rare variants, complex cases and antenatal risk assessment, consultation and collaboration with an experienced reference laboratory specialised in molecular analysis is encouraged.

Handling editor Mary Frances McMullin.

Acknowledgements The authors thank the members of the family, who gave their written informed consent for publication of this report.

Contributors All authors contributed to the study and have reviewed the manuscript. RH, attending physician, contributed to formal analysis, investigation, writing–original draft, writing–review & editing, supervision, visualisation. A-MF contributed to formal analysis, investigation, methodology, writing–review & editing. NL contributed to formal analysis, investigation, writing–review & editing. XP contributed to investigation, methodology, writing–review & editing. A-SA contributed to investigation, methodology, writing–review & editing. BG contributed to methodology, writing–review & editing. MVE contributed to methodology, supervision, writing–review & editing.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient consent for publication Consent obtained directly from patient(s).

Ethics approval This study involves human participants but was not approved by Institutional Board approval is not required for publication of reports, provided the subjects gave their written informed consent Participants gave informed consent to participate in the study before taking part.

Provenance and peer review Not commissioned; externally peer reviewed.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iD Ralph Huits http://orcid.org/0000-0001-8803-9468

REFERENCES
1. Kohne E. Hemoglobinopathies: clinical manifestations, diagnosis, and treatment. Dtsch Arztebl Int 2011;108:532–40.
2. Gullis B, Ferster A, Vertongen F, et al. Hemoglobinopathies in Belgium. Belg J Hematol 2010:50–6.
3. Weatherall DJ, Clegg JB. Inherited haemoglobin disorders: an increasingly global health problem. Bull World Health Organ 2001;79:704–12.
4. Giordano PC. Strategies for basic laboratory diagnostics of the hemoglobinopathies in multi-ethnic societies: interpretation of results and pitfalls. Int J Lab Hematol 2013;35:465–79.
5. Ivaldi G, Barberio G, Harteveld CL, et al. HbA2 measurements in β-thalassemia and in other conditions. Thalassemia Reports 2014;4:45–8.
6. Singh SP, Gupta SC. Effectiveness of red cell osmotic fragility test with varying degrees of saline concentration in detecting beta-thalassaemia trait. Singapore Med J 2008;49:823–6.
7. Itano HA. A third abnormal hemoglobin associated with hereditary hemolytic anemia. Proc Natl Acad Sci U S A 1951;37:775–84.
8. Torres LdeS, Okumura JV, Silva DGHd, et al. Hemoglobin D-Punjab: origin, distribution and laboratory diagnosis. Rev Bras Hematol Hemoterap 2015;37:120–6.
9. Narayanan S, Mathew B, Sriivasu BY, et al. Effect of point mutation on structure–function correlation of hemoglobin variants, HbE and HbD Punjab. Amino Acids 2020;52:893–904.
10. Denic S, Soud A-K. Hemoglobin D-Punjab homozygotes and double heterozygotes in premarital screening: case presentations and minireview. EMED 2021;3:90–4.
11. Delacour H, Brandeix A, Kedzierewicz R, et al. β-thalassemia carriers in Afghanistan: a prevalence estimate. Ann Biol Clin 2013;71:503–4.
12. Black ML, Sinha S, Agarwal S, et al. A descriptive profile of β-thalassaemia mutations in India, Pakistan and Sri Lanka. J Community Genet 2010;1:149–57.
13. Haldane JBS. The rate of mutation of human genes. Hereditas 1949;35:267–73.
14. Taylor SM, Parobek CM, Fairhurst RM. Haemoglobinopathies and the clinical epidemiology of malaria: a systematic review and meta-analysis. Lancet Infect Dis 2012;12:457–68.
15. Sally K, Saadat M. Consanguineous marriages in Afghanistan. J Biosoc Sci 2012;44:73–81.
16. Taghavi Basman J, Karimipoor M, Amirian A, et al. Co-inheritance of hemoglobin D and β-thalassemia traits in three Iranian families: clinical relevance. Arch Iran Med 2011;14:61–3.
17. Traeger-Synodinos J, Harteveld CL, Old JM, et al. EMON best practice guidelines for molecular and haematology methods for carrier identification and prenatal diagnosis of the haemoglobinopathies. Eur J Hum Genet 2015;23:426–37.
18. Premawardhena A, Arambepola M, Katugaha N, et al. Is the beta thalassaemia trait of clinical importance? Br J Haematol 2008;141:407–10.
19. Lobitz S, Telfer P, Cela E, et al. Newborn screening for sickle cell disease in Europe: recommendations from a pan-European consensus conference. Br J Haematol 2018;183:648–60.
20. Hoffmann JIML, Urechega E, Aguirre U. Discriminant indices for distinguishing thalassaemia and iron deficiency in patients with microcytic anaemia: a meta-analysis. Clin Chem Lab Med 2015;53:1883–94.